Chimeric antigen receptor T (CAR T) cell therapy represents a milestone in leukemia treatment. CAR T works by genetically ...

Consider the case of patient WB, a 79-year-old male with recurrent diffuse large B cell lymphoma. He was referred for ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

With clinical data beginning to emerge, big pharma is signaling its belief that in vivo CAR generation is the next immunotherapy breakthrough.

A new, highly sensitive cell therapy was able to wipe out three different kinds of solid tumors in mice, an important advance in an area where CAR-T cells have long struggled. But significant ...

After nearly a decade of treatment, a Texas woman reached remission through an FDA-approved cellular therapy for chronic lymphocytic leukemia.

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...

CAR T-cell therapy re-engineers immune cells to target and eradicate high-risk blood cancers, offering potential cures where traditional chemotherapy fails. Initially requiring inpatient care due to ...

A Phase 1 trial testing TG Therapeutics' CAR T-cell therapy azer-cel in progressive forms of MS is now recruiting across ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

A naturally occurring byproduct of liver metabolism—the ketone body, β-hydroxybutyrate (BHB)—can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 ...